Effects of Celecoxib on Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: Celecoxib, a double-edged sword for patients with angina

European Heart Journal

Volumn 33, Issue 21, 2012, Pages 2653-2661

  Kang, Hyun Jae ^a   Oh, Il Young ^b   Chung, Jin Wook ^c   Yang, Han Mo ^a   Suh, Jung Won ^b   Park, Kyung Woo ^a   Kwon, Taek Keun ^d   Lee, Hae Young ^a   Cho, Young Seok ^b   Youn, Tae Jin ^b   Koo, Bon Kwon ^a   Kang, Won Yu ^e   Kim, Weon ^f   Rha, Seung Woon ^g   Bae, Jang Ho ^d   Chae, In Ho ^b   Choi, Dong Ju ^b   Kim, Hyo Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Konyang University College of Medicine   (South Korea)

^e Kwangju Veterans Hospital   (South Korea)

^f Kyung Hee University College of Medicine   (South Korea)

^g Korea University College of Medicine   (South Korea)

Author keywords

Celecoxib; Drug eluting stent; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; ENDEAVOR ZES; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; TAXUS LIBERTE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ADD ON THERAPY; ADULT; ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; THROMBOSIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; ATHEROSCLEROSIS; BLOOD PRESSURE; CORONARY RESTENOSIS; CYCLOOXYGENASE 2 INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPERPLASIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOINTIMA; PROSPECTIVE STUDIES; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84868573383     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs001     Document Type: Article

References (27)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323. (Pubitemid 37186209)
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231. (Pubitemid 38067635)
3. Cosgrave J, Agostoni P, Ge L, Iakovou I, Chieffo A, Biondi-Zoccai GG, Sangiorgi GM, Montorfano M, Michev I, Airoldi F, Carlino M, Corvaja N, Bonizzoni E, Colombo A. Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol 2005;96:1663-1668. (Pubitemid 41790388)
4. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Agostoni P, Babic R, Airoldi F, Chieffo A, Sangiorgi GM, Montorfano M, Michev I, Carlino M, Colombo A. Comparable clinical outcomes with paclitaxel-and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 2007;49:2320-2328. (Pubitemid 46900991)
5. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275: 11397-11403. (Pubitemid 30212792)
6. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245-4249. (Pubitemid 28450018)
7. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, Walsh K. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004;110:301-308. (Pubitemid 38955499)
8. Koo BK, Kim YS, Park KW, Yang HM, Kwon DA, Chung JW, Hahn JY, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Effect of Celecoxib On REstenosis after coronary Angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet 2007;370:567-574.
9. Chung JW, Yang HM, Park KW, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Koo BK, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial. Circ Cardiovasc Interv 2010;3:243-248.
10. Lin HP, Kulp SK, Tseng PH, Yang YT, Yang CC, Chen CS. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 2004;3: 1671-1680. (Pubitemid 40136723)
11. Colleselli D, Bijuklic K, Mosheimer BA, Kahler CM. Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. Exp Cell Res 2006; 312:2933-2941.
12. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884. (Pubitemid 44315980)
13. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952. (Pubitemid 30419089)
14. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation 2007;115:2352-2357. (Pubitemid 46685904)
15. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806. (Pubitemid 44268230)
16. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007;49: 1676-1683. (Pubitemid 46589927)
17. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007;100:1103-1108. (Pubitemid 47404466)
18. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLAREDIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181-1187. (Pubitemid 351382092)
19. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-89. (Pubitemid 28312083)
20. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-855. (Pubitemid 32778031)
21. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-895. (Pubitemid 44315981)
22. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102. (Pubitemid 40365350)
23. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assoc 2006;296:1633-1644. (Pubitemid 44511610)
24. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005;365:475-481. (Pubitemid 40215729)
25. Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Luscher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, Graham DY, Yeomans ND, Krum H, Ruschitzka F, Lincoff AM, Nissen SE. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J 2009;157:606-612.
26. Lee W, Suh JW, Yang HM, Kwon DA, Cho HJ, Kang HJ, Kim HS, Oh BH. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J 2010;40:321-327.
27. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117: 2104-2113. (Pubitemid 351572169)